TREVI THERAPEUTICS INC (TRVI)

Company Profile

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. The company is headquartered in New Haven, Connecticut and currently employs 25 full-time employees. The company went IPO on 2019-05-07. The firm is focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed k-opioid receptor agonist and mu-opioid receptor antagonist. The company is conducting Phase IIb/III clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. The company is also conducting a Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as the Phase II CANAL trial. The Company’s Haduvio development programs include Active Chronic Pruritus Programs and Active Chronic Pruritus Programs. The Company’s subsidiary is Trevi Therapeutics Limited.

Company Info

TREVI THERAPEUTICS INC

195 Church St Fl 14

New Haven CONNECTICUT 06510

P: 12033042499

CEO: Jennifer Good

Employees: 25

Website: https://www.trevitherapeutics.com/